A randomised 2-arm, prospective, multi-centre, open-label, phase III trial comparing the activity and safety of a weekly vs a 3 weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer

Trial Profile

A randomised 2-arm, prospective, multi-centre, open-label, phase III trial comparing the activity and safety of a weekly vs a 3 weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 10 Jun 2010 Additional lead trial centres (Bristol Myers Squibb and Common Services Agency, NHS Scotland) identified as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Additional trial locations (England, Scotland and Wales) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top